Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Xtandi (enzalutamide) plus ADT significantly slows disease progression vs darolutamide plus ADT in patients with mHSPC, according to a matching-adjusted indirect comparison analysis published in Future Oncology.

July 18, 2025

Vol.51 No.28

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes using an existing class of autoimmune drugs.

July 11, 2025

Vol.51 No.27

Clinical Roundup

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma resist thermal ablation and even thrive after being treated with high heat, according to a study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Cardiac biomarkers linked to future cancer risk, even without heart disease, says UCLA prospective cohort study

Certain cardiac blood markers can strongly predict future cancer risk—even in people with no history or symptoms of heart disease, according to a UCLA Health study.

July 11, 2025

Vol.51 No.27

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

YOU MAY BE INTERESTED IN

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Cardiac biomarkers linked to future cancer risk, even without heart disease, says UCLA prospective cohort study

Renew today!

Subscriber content

Never miss an issue!

Login